Panobinostat (LBH589)

目录号：S1030 别名： NVP-LBH589

Molecular Weight(MW): 349.43

Panobinostat (LBH589)是一种新型的，广谱HDAC抑制剂，无细胞试验中IC50为5 nM。Phase 3。

规格

价格

库存

购买数量

10mg	RMB 731.86	现货
50mg	RMB 2189.52	现货
200mg	RMB 5485.18	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck该产品发表文献52篇：

Cell, 2018, 173(6):1413-1425

PubMed: 29754815 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3941-3954

PubMed: 29764852 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(1):120-129.

PubMed: 29066507 ( click the link to review the publication )

Blood, 2016, 127(10):1325-35

PubMed: 26668133 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(10):2534-44

PubMed: 26733615 ( click the link to review the publication )

Biomed Pharmacother, 2016, 84:1393-1405

PubMed: 27802904 ( click the link to review the publication )

PLoS One, 2016, 11(2):e0148912

PubMed: 26859414 ( click the link to review the publication )

JCI Insight, 2016, 1(5):e85061

PubMed: 27699258 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Ann Rheum Dis, 2015, 10.1136/annrheumdis-2014-206258

PubMed: 25589513 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: ( click the link to review the publication )

J Biol Chem, 2015, 10.1074.jbc.M114.624361

PubMed: 25737447 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: ( click the link to review the publication )

Western University, 2015, Western University

PubMed: ( click the link to review the publication )

Cell, 2014, 159(5):1110-25

PubMed: 25416949 ( click the link to review the publication )

Cancer Lett, 2014, 356(2 Pt B):656-68

PubMed: 25458954 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

PLoS Pathog, 2014, 10(8):e1004287

PubMed: 25122219 ( click the link to review the publication )

Anal Chem, 2014, 86(10):4642-7

PubMed: 24559101 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Br J Haematol, 2014, 167(5):639-50

PubMed: 25155625 ( click the link to review the publication )

J Immunol, 2014, 193(3):1333-43

PubMed: 24973453 ( click the link to review the publication )

BMC Cancer, 2014, 14:17

PubMed: 24418474 ( click the link to review the publication )
PLoS One, 2014, 10(8):e1004287

PubMed: 25122219 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 452(3):649-54

PubMed: 25193706 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Commun, 2013, 4:2735

PubMed: 24193185 ( click the link to review the publication )

Leukemia, 2013, 27(6):1291-300

PubMed: 23411464 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Cancer Lett, 2013, 329(1):17-26

PubMed: 22995071 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(4):R58

PubMed: 23879992 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Br J Haematol, 2013, 162(4):559-62

PubMed: 23692150 ( click the link to review the publication )

Radiother Oncol, 2013, 108(3):429-33

PubMed: 23932191 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2013, 139(9):1507-14

PubMed: 23824064 ( click the link to review the publication )

PLoS One, 2013, 8(11):e79106

PubMed: 24244429 ( click the link to review the publication )

PLoS One, 2013, 8(9):e76662

PubMed: 24098799 ( click the link to review the publication )

PLoS One, 2013, 8(7):e69992

PubMed: 23922886 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Theriogenology, 2013, 80(6):630-5

PubMed: 23866857 ( click the link to review the publication )

Protein Expr Purif, 2013, 92(1):119-127

PubMed: 24056254 ( click the link to review the publication )

The University of Western Ontario, 2013, CHAE YOUNG HAN

PubMed: ( click the link to review the publication )

Blood, 2012, 119(6):1450-8

PubMed: 22144178 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(2):408-16

PubMed: 22038994 ( click the link to review the publication )

Breast Cancer Res Tr, 2012, 131(3):777-89

PubMed: 21452019 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )
Acta Neuropathol, 2011, 122(5):637-50

PubMed: 21863243 ( click the link to review the publication )

PLoS One, 2011, 6(2):e17138

PubMed: 21359182 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

Biochem Bioph Res Co, 2010, 391(4):1748-51

PubMed: 20043870 ( click the link to review the publication )

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述

Panobinostat (LBH589)是一种新型的，广谱HDAC抑制剂，无细胞试验中IC50为5 nM。Phase 3。

靶点

HDAC (MOLT-4 cells) ^[1]	HDAC (Reh cells) ^[1]
5 nM	20 nM

体外研究

LBH589诱导MOLT-4和Reh细胞凋亡，这种作用具有时间和剂量依赖性。而且，LBH589作用于MOLT-4细胞比作用于Reh细胞更有效。LBH589明显阻止MOLT-4 和Reh细胞的生长，处理48小时，具有剂量依赖性。与对照组细胞相比，用LBH589处理的细胞，在细胞周期的G2/M期的细胞数量增多2到3倍。LBH589与组蛋白H3K9和H4K8的乙酰化作用相关，LBH589也降低c-Myc的表达水平，具有剂量依赖性。LBH589也增强p21的表达水平。最低剂量的LBH589（10 nM）处理Reh细胞，最初增强c-Myc的表达水平，之后一直降低c-Myc的表达水平。此外，LBH589促进mRNA水平的促凋亡和DNA修复基因的大量增多。在GADD45G启动子作用下，LBH589诱导乙酰化的组蛋白H3 和H4水平的增多。^[1]此外, LBH589抑制非小细胞肺癌细胞系生长，如人类H1299,L55和A549，IC50分别为5,11和30 nM；间皮瘤细胞生长，如人类OK-6和 Ok-5，IC50分别为5和7 nM；及小细胞肺癌细胞系生长，如人类RG-1和LD-T，IC50分别为4和5 nM。^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HT29	NUHzSnBRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XTdlAuOTBizszN	NXTS[nNwOC12IHS=		M2XIUIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NVjmdVRqOjZ5MEK3PFQ>
HepG2	MorsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV6wMVExKM7:TR?=	MXSwMVQh\A>?		M1PnV4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M3jLNlI3PzB{N{i0
HT29	NWLMRXp5TnWwY4Tpc44hSXO\|YYm=	MX21NOKhdk1?	NH;YSY4zPC15MjDo		M{iwfIlv\HWlZXSgZYN1cX[jdHnvckBw\iClYYPwZZNmKDNiYX\0[ZIhPDkEoHlCpC=>	NILSZXUzPjdyMke4OC=>
HepG2	NWqzXlNpTnWwY4Tpc44hSXO\|YYm=	NEL3[og2OMLibl2=	MnvaNlQuPzJiaB?=		MWHpcoR2[2WmIHHjeIl3[XSrb36gc4Yh[2G\|cHHz[UA{KGGodHXyJFI1yqCqwrC=	M4r3RlI3PzB{N{i0
HCC827	NWTUS3AzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW[1M\|cvPS9zMDDuUS=>	NGjpXWE4OsLiaB?=	MmL6SG1UVw>?	M{m0NYVvcGGwY3XzJJRp\SCjboTpdJJwdGmoZYLheIl3\SCnZn\lZ5Qhd2ZiZYLsc5Rqdmmk	MWOyOlY4PTR6NB?=
A549	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzieG4yOC9zNT:yNEBvVQ>?	MknOO\|LDqGh?	NYfVWGZFTE2VTx?=	NXzZZVZW\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK=	MmfRNlY3PzV2OES=
NCI-H460	MkjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTvSlB4OTBxMkCvN\|Ahdk1?	MljvO\|LDqGh?	MoX2SG1UVw>?	MVnlcohidmOnczD0bIUh[W62aYDyc4xq\mW{YYTpeoUh\W[oZXP0JI9nKGW{bH;0bY5q[g>?	MXiyOlY4PTR6NB?=
J89GFP	M1nPU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWKzXG05TE2VT9Mg	NXLVdFZxTUN3ME20PU45PSEEsTCxNk43PSCwTR?=	NEXyfZozPjV4M{W2PC=>
THP89GFP	M1SyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVXEUXNQyqB?	NWPXSmFDTUN3ME2xPU4{PCEEsTC2MlQ{KG6P	M2D2b\|I3PTZ\|NU[4
SK-NEP-1	MorwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWn0d3pYOC5yMfMAl\|ExNjBizszN	MVqyOEBp	MkPBSG1UV8Li	MXrJR\|UxRTd4LkO0JI5O	NF\C[FAzPjF5NkKxPS=>
G401	M3jmOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVH4b3p6OC5yMfMAl\|ExNjBizszN	Mnz3NlQhcA>?	M2jNZmROW00EoB?=	NGrF[\|dKSzVyPUG0N{4xOiCwTR?=	M{fzTlI3OTd4MkG5
SK-NEP-1	NWjBXlV1S2WubDDWbYFjcWyrdImgRZN{[Xl?	M{e2bVUxKG6P	NEL0[Ysy6oDVNDDk	MmixSG1UV8Li	MnnudoVlfWOnczDj[YxtKHO3co\peoFtKGmwIHGgeIlu\SCmZYDlcoRmdnRibXHucoVz	M4TpclI3OTd4MkG5
G401	Mm\ER4VtdCCYaXHibYxqfHliQYPzZZk>	NVvXTZJ2PTBibl2=	NFPtZmky6oDVNDDk	MoSzSG1UV8Li	NGLGRYlz\WS3Y3XzJINmdGxic4Xyeol3[WxiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ?	M{Gxe\|I3OTd4MkG5
SK-NEP-1	M2Xn[2Fxd3C2b4Ppd{BCe3OjeR?=	MlryOVAwOTByIH7N	M1XWTlI1KGh?	NGnod41FVVORwrC=	NVWzfoE6cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NHvWSYczPjF5NkKxPS=>
G401	NXrGTpV[SXCxcITvd4l{KEG\|c3H5	NEj3RnQ2OC9zMECgcm0>	NETTTHczPCCq	NYjacFdPTE2VT9Mg	NEnqUnNqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MYSyOlE4PjJzOR?=
SK-NEP-1	M1LGbWZ2dmO2aX;uJGF{e2G7	NYXoemFIPTBxMUCwJI5O	NIHIUJgzPCCq	NFfGd3BFVVORwrC=	MU\zbI94eyC2aHWgbY5lfWO2aX;uJI9nKESQQTDmdoFodWWwdHH0bY9v	M1;XU\|I3OTd4MkG5
G401	M1SyS2Z2dmO2aX;uJGF{e2G7	NX71dHR3PTBxMUCwJI5O	MX[yOEBp	MY\EUXNQyqB?	MVTzbI94eyC2aHWgbY5lfWO2aX;uJI9nKESQQTDmdoFodWWwdHH0bY9v	M4HseFI3OTd4MkG5
SK-NEP-1	MV7GeY5kfGmxbjDBd5NigQ>?	M1TUW\|UxNzFyMDDuUS=>	NYfwSXA6OjRiaB?=	MXfEUXNQyqB?	MYPpcoR2[2W\|IHPlcIwh[3mlbHWg[Il{d3KmZYNCpC=>	M2\3PVI3OTd4MkG5
G401	Mn:zSpVv[3Srb36gRZN{[Xl?	Ml;1OVAwOTByIH7N	NU\JVFFEOjRiaB?=	MUTEUXNQyqB?	M4XhNIlv\HWlZYOgZ4VtdCCleXPs[UBlcXOxcnTlduKh	M{TyZ\|I3OTd4MkG5
RPMI 8226	M{D0XWNmdGxiU4Xyeol3[WxiQYPzZZk>	NWDtNVhoOi92L{[gcm0>	M2XOXFQ56oDLaB?=		MULpcoR2[2W\|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp	NV;sVFVqOjZyMECyPVI>
OPM2	NEjB[HFE\WyuIGP1dpZqfmGuIFHzd4F6	MmfkNk81NzZibl2=	Mnr1OFjjiImq		Mnv5bY5lfWOnczDhJJNq\26rZnnjZY51KGSnY4LlZZNmKGmwIITo[UBk\WyuIHfyc5d1cA>?	NITOeFEzPjByMEK5Ni=>
U266	M1PrfGNmdGxiU4Xyeol3[WxiQYPzZZk>	NEDWNIgzNzRxNjDuUS=>	NFvNcpg1QOLCiXi=		NFjP[HNqdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq	MoDBNlYxODB{OUK=
H929	MmTsR4VtdCCVdYL2bZZidCCDc4PhfS=>	M2\2bFIwPC94IH7N	MVK0PQKBkWh?		NVrURmpIcW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?=	M2DtZ\|I3ODByMkmy
RPMI 8226	MU\BdI9xfG:\|aYOgRZN{[Xl?	NHnhN3c16oDLbl2=	NEDGSVYzPC92ODDo		M2\HWYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUB1cW2nLXTldIVv\GWwdDDtZY5v\XJ?	MVGyOlAxODJ7Mh?=
HCC827	NHXZ[YxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYOxNEBvVQ>?	MnHUOFghcA>?	MUnEUXNQ	NX3KXZNT\W6qYX7j[ZMh[2m\|cHzheIlvKHOnboPpeIl3cXS7wrC=	NF22OoYzPTl2NE[xOy=>
NCI-H23	NVPrT5k4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYjIOW17OTBibl2=	MoHKOFghcA>?	NVq1ZlhNTE2VTx?=	MWrlcohidmOnczDjbZNxdGG2aX6gd4Vve2m2aY\peJnDqA>?	MX6yOVk1PDZzNx?=
AML3	Mm\aSpVv[3Srb36gRZN{[Xl?	M3P5S\|AuOSEQvF2=	MljzNlTDqGh?		M4LCPIlv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MUCyOVYyOjl2MR?=
ML-1	MXrGeY5kfGmxbjDBd5NigQ>?	M4DwVFAuOSEQvF2=	NYDnPWtROjUEoHi=		NVf4S25pcW6mdXPld{BFVkFiZoLh[41mdnSjdHnvcuKhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	M3n3Z\|I2PjF{OUSx
RPMI-8226vr10	MWDGeY5kfGmxbjDBd5NigQ>?	MXywMVEh\|ryP	M4PmTVI1yqCq		NVTWWHc5cW6mdXPld{BFVkFiZoLh[41mdnSjdHnvcuKhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NUiyT2ZTOjV4MUK5OFE>
ML-1	MmfrSpVv[3Srb36gRZN{[Xl?	NVr1NVQ4OSEQvF2=	NYf4SWJNOjUEoHi=		MUPpcoNz\WG\|ZYOgZ4F{eGG\|ZT2zJIFkfGm4aYT5JFQu\m:uZB?=	MoK0NlU3OTJ7NEG=
RPMI-8226vr10	NHvxXFJHfW6ldHnvckBCe3OjeR?=	MoDONUDPxE1?	MYSyOOKhcA>?		M2DXfYlv[3KnYYPld{Bk[XOyYYPlMVMh[WO2aY\peJkhOi53LX\vcIQ>	M2rCVFI2PjF{OUSx
SK-N-BE (2)	M4m0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIrqe\|gzPOLCiXi=		MVnJR\|UxRTFyND6w5qCKyrIkgJm3Mlghdk1?	Moi1NlU{ODh7MU[=
SK-N-BE (2), PAN MK	M3;FfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHzBeGczPOLCiXi=		MkXHTWM2OD1zMESuNQKBkcLz4pEJO{45KG6P	M4PPVVI2OzB6OUG2
SK-N-BE (2), MK PAN	NFX4RWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4HhfVI16oDLaB?=		NIH1NFlKSzVyPUO4Nk4x6oDLwsJihKk1Oy5{IH7N	MoqwNlU{ODh7MU[=
SK-N-AS	NFzDdFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXfOUZhUOjUkgJno		NYPsenY5UUN3ME2zO{4y6oDLwsJihKkzNjRibl2=	MoDDNlU{ODh7MU[=
SK-N-DZ	M1\5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGrhOJUzPOLCiXi=		MnuyTWM2OD1zNz6x5qCKyrIkgJmwMlQhdk1?	M4L4d\|I2OzB6OUG2
Caki-1	NITlPJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2HUVVExNzJ3L{WwJI5O	NIHTUJM1QCCq		M1u5cIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIILpeI9v[X[rch?=	M{XjXlI2Ojd7MUmx
ACHN	Mlz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvIVJEyOC9{NT:1NEBvVQ>?	M1XIblQ5KGh?		NYPwdlM2cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigdol1d26jdnny	MUeyOVI4QTF7MR?=
769-P	MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYixNE8zPS93MDDuUS=>	NHHwUmw1QCCq		M3PTN4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIILpeI9v[X[rch?=	MoqxNlUzPzlzOUG=
786-O	MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYiwSlBlOTBxMkWvOVAhdk1?	NY\2PI5GPDhiaB?=		MXTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ?	NYq1RYI6OjV{N{mxPVE>
Caki-1	NXnMNXhDSXCxcITvd4l{KEG\|c3H5	MXG1NEBvVQ>?	M2T5N\|Q5KGh?		NVf0dI5pcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDjc41jcW6nZDDybZRwdmG4aYK=	Mn\tNlUzPzlzOUG=
ACHN	M1n6[WFxd3C2b4Ppd{BCe3OjeR?=	M2fOZVUxKG6P	NV73cXVTPDhiaB?=		NUHuPIEzcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDjc41jcW6nZDDybZRwdmG4aYK=	NGmy[3QzPTJ5OUG5NS=>
769-P	Mn\aRZBweHSxc3nzJGF{e2G7	MkPGOVAhdk1?	M33WVlQ5KGh?		NULSOGxKcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDjc41jcW6nZDDybZRwdmG4aYK=	MX:yOVI4QTF7MR?=
786-O	NGDH[WRCeG:ydH;zbZMhSXO\|YYm=	M1\LNlUxKG6P	NEfhV4Q1QCCq		MXXpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGOxbXLpcoVlKHKrdH;uZZZqeg>?	MUOyOVI4QTF7MR?=
Caki-1	NFXzW29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HJR\|I2NzVyIH7N	Mn;OOFghcA>?	NGT4[GVFVVOR	MX;pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCCkb4L0[ZpwdWmk	M1LUWlI2OTd4M{W0
ACHN	Mmi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LZZVI2NzVyIH7N	NIrNWFk1QCCq	NIjCSJBFVVOR	NILBV3JqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC\|eX7ldodqe3SrY3HscJkhf2m2aDDic5J1\XqxbXni	MV2yOVE4PjN3NB?=
769-P	Mni5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jqTFI2NzVyIH7N	MlT0OFghcA>?	NVzONXBRTE2VTx?=	NYW2d\|JPcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigZo9zfGW8b33pZi=>	M3\RdFI2OTd4M{W0
Caki-1	NXWwXG9NS2:ub375JGZwem2jdHnvckBCe3OjeR?=	NHHmR5k2OCCwTR?=	NV\ROY8zPy1zNDDk	MULEUXNQ	M2jQO5N2eHC{ZYPz[YQh[2:ub375JIZwem2jdHnvckB{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghf2m2aDDic5J1\XqxbXniJOKh	M3rwdVI2OTd4M{W0
ACHN	NF;p[XVEd2yxbomgSo9zdWG2aX;uJGF{e2G7	NYe4O5pRPTBibl2=	M2r0OFcuOTRiZB?=	NF\MUXFFVVOR	MULzeZBxemW\|c3XkJINwdG:weTDmc5Ju[XSrb36gd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJJdqfGhiYn;yeIV7d22rYjFCpC=>	M2DCZ\|I2OTd4M{W0
769-P	Ml;CR49td267IF\vdo1ifGmxbjDBd5NigQ>?	MmPrOVAhdk1?	M{\4TVcuOTRiZB?=	M3SzR2ROW09?	NFXVfWt{fXCycnXzd4VlKGOxbH;ufUBnd3KvYYTpc44he2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKHerdHigZo9zfGW8b33pZkDDqA>?	NGPXRZIzPTF5NkO1OC=>
Caki-1	NEHocphCeG:ydH;zbZMhSXO\|YYm=	NFHJbo42OCCwTR?=	MmXGOFghcA>?	NY[zfFd{TE2VTx?=	M4LZd4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	Ml;PNlUyPzZ\|NUS=
ACHN	M1:wemFxd3C2b4Ppd{BCe3OjeR?=	NGfuV2U2OCCwTR?=	NWfIR2s4PDhiaB?=	NGTGPGFFVVOR	MX;pcoR2[2W\|IHPlcIwh[XCxcITvd4l{	M1f2fVI2OTd4M{W0
769-P	Mkj1RZBweHSxc3nzJGF{e2G7	NGDkdlY2OCCwTR?=	MVi0PEBp	NEHndZNFVVOR	NVntSpRlcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	M376TVI2OTd4M{W0
MDA-MB-231	MVTNc5JxcG:ub3fpZ4FtKEO{eYP0ZYwhXmmxbHX0JEhEXiliQYPzZZk>	M1TNd\|ExyqCwTR?=	MUWzxsBl	MV\EUXNQ	Mnr3ZYx1\XK\|IHPlcIwhdW:{cHjvcI9ogcLi	MnPmNlQ5OTB2OUe=
BT-549	NV\jWpVGVW:{cHjvcI9ocWOjbDDDdpl{fGGuIG\pc4xmfCBqQ2[pJGF{e2G7	MlTKNVDDqG6P	NXf1OpFtO8LiZB?=	M1XIcmROW09?	MXHhcJRmenNiY3XscEBud3KyaH;sc4d6yqB?	NGrt[GUzPDhzMES5Oy=>
MCF-7	MoT5UY9zeGixbH;nbYNidCCFconzeIFtKF[rb3zleEApS1ZrIFHzd4F6	MnG2NVDDqG6P	MoqyN:Kh\A>?	M1\GfmROW09?	M3;mc4FtfGW{czDj[YxtKG2xcoDoc4xw\3oEoB?=	MmXlNlQ5OTB2OUe=
MCF-7	MVzGeY5kfGmxbjDBd5NigQ>?	M4jxW\|UuPTBibl2=	NHfHS28zPCCq	NELQcmNFVVOR	MVjy[YR2[2WmIITo[UBt\X[nbDDv[kBmgHC{ZYPzbY9vKG:oIFXS{tEtKFCUIHHu[EBHd3iDMdMg	NVPNN2xjOjR\|Nk[0NFc>
CTS	NIX2eo5CeG:ydH;zbZMhSXO\|YYm=	MYWw5qCUPDBibl5CpC=>	NH:zNJQ1QCCq		Mon4bY5lfWOnczDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NFuyWFkzPDJ2NESyPS=>
OCI-AML3	NWPuVopoSXCxcITvd4l{KEG\|c3H5	MmrINQKBmzRyIH7NxsA>	NWLFVoU4PDhiaB?=		M4PxWIlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MmC2NlQzPDR2Mkm=
U937	M4DCVGFxd3C2b4Ppd{BCe3OjeR?=	NGfSbGYx6oDVNECgcm3DqA>?	NXnBWXFIPDhiaB?=		MX3pcoR2[2W\|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	Mly1NlQzPDR2Mkm=
PC3	MnPCRZBweHSxc3nzJGF{e2G7	MWiwMVExOCCwTR?=	M2DP[FI1NzR6IHi=		MoXybY5lfWOnczDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NEDkb\|kzPDF4M{KzNC=>
PC3-AR	NV;0VXhRSXCxcITvd4l{KEG\|c3H5	NWjs[ZFtOC1zMECgcm0>	NWXaOXo3OjRxNEigbC=>		MXTpcoR2[2W\|IHHwc5B1d3OrczDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MnXSNlQyPjN{M{C=
PC3	M364UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVewMVExOCCwTR?=	NXrUbo5QOjRxNEigbC=>		MV;pcoR2[2W\|IHHjZ5VufWyjdHnvckBw\iC\|dXLHNUBxd3C3bHH0bY9v	NXvub3hTOjRzNkOyN\|A>
PC3-AR	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4Tyd\|AuOTByIH7N	Mnz6NlQwPDhiaB?=		MlTpbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW\|dDDpckB1cGViR{LNJJBp[XOn	MYOyOFE3OzJ\|MB?=
PC3	M{XNXmZ2dmO2aX;uJGF{e2G7	MWGwMVExOCCwTR?=	M1fSflI1KGh?		NES5bXB{fXCycnXzd4V{KGW6cILld5Nqd25ib3[gZYN1cX[jdHXkJGFVVSxiQXv0JIFv\CCHcnuxM\|IheHKxdHXpci=>	NGD3OmMzPDF4M{KzNC=>
PC3-AR	NIrqUmlHfW6ldHnvckBCe3OjeR?=	MV6wMVExOCCwTR?=	MnPMNlQhcA>?		M1G5XpN2eHC{ZYPz[ZMh\XiycnXzd4lwdiCxZjDhZ5RqfmG2ZXSgRXRONCCDa4SgZY5lKEW{a{GvNkBxem:2ZXnu	Mk\pNlQyPjN{M{C=
OS-RC-2	NWH4ZpE6S2WubDDWbYFjcWyrdImgRZN{[Xl?	M1LyPVAuOTByMDDuUS=>	MYqyOE81QC95MjDo	MV3EUXNQ	M3\veYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MlP6NlQyPDR5M{e=
OS-RC-2	NFn2UnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYnBflNxPTBibl2=	NUjhXYVxPDhiaB?=	NV:3NFc{TE2VTx?=	M4j0cIlv\HWlZYOgS\|IwVSCjcoLld5Q>	MU[yOFE1PDd\|Nx?=
OS-RC-2	MWTBdI9xfG:\|aYOgRZN{[Xl?	MX61NEBvVQ>?	M4PscVQ5KGh?	M2DUe2ROW09?	NIr2cndqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	NX3GXnZ4OjRzNES3N\|c>
SK-N-AS	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFj6TIIx6oDVOECgcm0>	NHzmU4I1QCCq		MmH0TWM2OD1{Nz60JI5O	NYnjdZp{OjRyOUi3PVk>
SK-N-DZ	NV7GVo9yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXWw5qCUQDBibl2=	NWLtOYY5PDhiaB?=		MmLPTWM2OD1{MT65JI5O	NIW0UJQzPDB7OEe5PS=>
SK-N-SH	NXjFUo1RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX6w5qCUQDBibl2=	M4TqUVQ5KGh?		NHXVXJFKSzVyPUeyMlMhdk1?	Mk[0NlQxQTh5OUm=
SK-N-BE	NWDIPJRRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTETmRROOLCk{iwJI5O	Mn;TOFghcA>?		MWPJR\|UxRTd3LkSgcm0>	NGHmeJczPDB7OEe5PS=>
SK-N-AS	Mn7mRZBweHSxc3nzJGF{e2G7	MWSw5qCUQDBibl2=	MXW0PEBp		NHvrTZRxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44>	M3u3UFI1ODl6N{m5
SK-N-DZ	NGmzNpBCeG:ydH;zbZMhSXO\|YYm=	NW\6dWpbOOLCk{iwJI5O	M1raRVQ5KGh?		M{fpS5BwfGWwdHz5JIlv\HWlZXSgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQh\mG\|aHnvci=>	NUfjVG45OjRyOUi3PVk>
SK-N-SH	NYHwPYo5SXCxcITvd4l{KEG\|c3H5	Ml\INQKBmzRyIH7N	NI\n[GI1QCCq		NWfFSId[eG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v	NUHNfpplOjRyOUi3PVk>
SK-N-BE	MW\BdI9xfG:\|aYOgRZN{[Xl?	NFPHe2Yx6oDVNECgcm0>	Mkf1OFghcA>?		MmHZdI91\W62bImgbY5lfWOnZDDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u	MUiyOFA6QDd7OR?=
SK-N-AS	MmrkSpVv[3Srb36gRZN{[Xl?	M1TnW\|DjiJN6MDDuUS=>	NY[ze4l{PDhiaB?=		NGWwN3VqdmS3Y3XzJIEh\G:\|ZT3k[ZBmdmSnboSgZ4xm[X[jZ3Wgc4Yh[2G\|cHHz[UA{KGGwZDDQRXJR	M3zRVVI1ODl6N{m5
SK-N-DZ	MlLOSpVv[3Srb36gRZN{[Xl?	NIPMTFkx6oDVOECgcm0>	M1z1WVQ5KGh?		MkC3bY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=>	NYrUNGc3OjRyOUi3PVk>
SK-N-SH	NH;FbVFHfW6ldHnvckBCe3OjeR?=	NVX1Xpc3OOLCk{SwJI5O	M4HKV\|Q5KGh?		MVHpcoR2[2W\|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG\|ZTCzJIFv\CCSQWLQ	NILwVoYzPDB7OEe5PS=>
SK-N-BE	MojHSpVv[3Srb36gRZN{[Xl?	NWXLbVR6OOLCk{SwJI5O	NIj4[Wc1QCCq		MVvpcoR2[2W\|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG\|ZTCzJIFv\CCSQWLQ	NFLPWYozPDB7OEe5PS=>
HCC-LM3	M2ntfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\LVHoyNTFyMECgcm0>	NH25SXMzPC92OD:3NkBp	MULEUXNQ	M3;wfYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NHTEXIczPDB7M{m1Oi=>
HepG2	NX7vOpJRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPVNU0yODByIH7N	MV6yOE81QC95MjDo	MnrvSG1UVw>?	MlGwbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	M2m1RVI1ODl\|OUW2
SMMC-7721	MoHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjsOpVqOS1zMECwJI5O	MXiyOE81QC95MjDo	NF65c\|NFVVOR	M2\hXIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NF;idG0zPDB7M{m1Oi=>
HCC-LM3	M2\ocGFxd3C2b4Ppd{BCe3OjeR?=	NG\sOmE2OCCwTR?=	NUHGbWdvPDhiaB?=	MVvEUXNQ	M1r1Oolv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6	NXjZS3JVOjRyOUO5OVY>
HepG2	MonlRZBweHSxc3nzJGF{e2G7	Mny4OVAhdk1?	NWDiVldlPDhiaB?=	NGTDbY5FVVOR	NV:2WnBXcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGmwIHGgZ4F{eGG\|ZT3k[ZBmdmSnboSgcYFvdmW{IHL5JINt\WG4YXflJI9nKGOjc4Dhd4V{KDNuIEigZY5lKDl?	MWKyOFA6Ozl3Nh?=
SMMC-7721	M3;FbmFxd3C2b4Ppd{BCe3OjeR?=	MUC1NEBvVQ>?	MVS0PEBp	NIPXcGlFVVOR	M{HaXIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6	M{jW[FI1ODl\|OUW2
HCC-LM3	MUjGeY5kfGmxbjDBd5NigQ>?	NEPkR\|E2OC9zMECgcm0>	MWmyOEBp	NUHYNohCTE2VTx?=	M{jmSIRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIICtV3RCXDNiYX7kJJAuSWu2wrC=	M3\MTlI1ODl\|OUW2
HepG2	NIHlN2VHfW6ldHnvckBCe3OjeR?=	NYOyN4JjPTBxMUCwJI5O	MWKyOEBp	MULEUXNQ	NGjxdVVl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDwMXNVSVR\|IHHu[EBxNUGtdNMg	NEPlfYwzPDB7M{m1Oi=>
SMMC-7721	MnjYSpVv[3Srb36gRZN{[Xl?	NXLWZ4dtPTBxMUCwJI5O	M4XTVlI1KGh?	MkK2SG1UVw>?	M3\ZT4Rm[3KnYYPld{B1cGVibHX2[Yx{KG:oIICtV3RCXDNiYX7kJJAuSWu2wrC=	NUjiU2tiOjRyOUO5OVY>
HCC-LM3	NIX2XIpHfW6ldHnvckBCe3OjeR?=	MXq1NE8yODBibl2=	NXXqbJV[OjRiaB?=	Ml3BSG1UVw>?	NFW4fGtld3ewcnXneYxifGW\|IFLjcE15VCCneIDy[ZN{cW:w	MkDINlQxQTN7NU[=
HepG2	MknOSpVv[3Srb36gRZN{[Xl?	M2rs[VUxNzFyMDDuUS=>	Mn3kNlQhcA>?	NEOwZWtFVVOR	MnLI[I94dnKnZ4XsZZRmeyCEY3ytfGwh\XiycnXzd4lwdg>?	NH7WSYYzPDB7M{m1Oi=>
SMMC-7721	MVzGeY5kfGmxbjDBd5NigQ>?	MmrkOVAwOTByIH7N	NEPUS2EzPCCq	M2HkVGROW09?	MYfkc5dvemWpdXzheIV{KEKlbD34UEBmgHC{ZYPzbY9v	MYOyOFA6Ozl3Nh?=
FaDu	NEXER29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fUSFExOOLChX7N	NUC5VoZJQC9zMD:xNkBp		NXPRVVlm\Gm\|cHzhfYVlKGFic3nncolncWOjboSgZY5lKHC{b3zvcodm\CCJMj;NJIFzemW\|dDDheEA5KGGwZDCxNwKBjWhicH;zeEBz\WynYYPl	MkHENlQxOjZ2OEK=
FaDu	MXTGeY5kfGmxbjDBd5NigQ>?	MkfyNVAx6oDHbl2=	M4CzZlIwPC96L{GyJIg>		MlK1bY5lfWOnZDDwNlFY[WZzL1PpdFHDqGW6cILld5Nqd25?	M1LW[\|I1ODJ4NEiy
PC-3	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PIUVAuOTBizszN	NGrPO3IzPC92OD:3NkBp		M2\RPIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MWCyN\|k6OTJzNh?=
LNCaP	NFHzSVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXiwMVUh\|ryP	MlTKNlQwPDhxN{KgbC=>		MU\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NHfiNo4zOzl7MUKxOi=>
RWPE-1	NUnrUJFYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnyRZVrOC1{MDFOwG0>	MoPNNlQwPDhxN{KgbC=>		MXXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M4\CZVI{QTlzMkG2
Capan-1	MVrGeY5kfGmxbjDBd5NigQ>?	NUHBPIpFOjVxNUCvNVAxKG6P	NWe1dVRsQC9{ND:0PEBp	M2j2OGROW09?	M2jTUYRwf26{ZXf1cIF1\WRiUn;uJI1TVkFiYX7kJJBzd3SnaX6g[ZhxemW\|c3nvckBidmRiZH;3cpN1emWjbTDzbYdv[Wyrbne=	M4q1WVI{QTJ{OEi2
L3.6pl	NGnyW3RHfW6ldHnvckBCe3OjeR?=	MkXENlUwPTBxMUCwJI5O	M3i4fVgwOjRxNEigbC=>	M1TpeWROW09?	MUXkc5dvemWpdXzheIVlKFKxbjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36gZY5lKGSxd37zeJJm[W1ic3nncoFtcW6p	M2jtSVI{QTJ{OEi2
CFPAC-1	NE\R[VhHfW6ldHnvckBCe3OjeR?=	MVWyOU82OC9zMECgcm0>	M1nJS\|gwOjRxNEigbC=>	MmPHSG1UVw>?	MVXkc5dvemWpdXzheIVlKFKxbjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36gZY5lKGSxd37zeJJm[W1ic3nncoFtcW6p	MUmyN\|kzOjh6Nh?=
Capan-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3K3NVI2NzVyL{GwNEBvVQ>?	NGnWNZk1QCCq	NWXUbHdxTE2VTx?=	MV7y[YR2[2W\|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NXW1R\|VuOjN7MkK4PFY>
L3.6pl	M2Ljfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYOyOU82OC9zMECgcm0>	Mo\tOFghcA>?	NFTNOWpFVVOR	MoiwdoVlfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	M1fGcVI{QTJ{OEi2
CFPAC-1	MmTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjYOWVxOjVxNUCvNVAxKG6P	NUW2b5p4PDhiaB?=	NH7OS5hFVVOR	NVPwWHBiemWmdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MnfPNlM6OjJ6OE[=
Capan-1	M2OwR2Fxd3C2b4Ppd{BCe3OjeR?=	MUSyOU82OC9zMECgcm0>	NG\5PZE1QCCq	MnnaSG1UVw>?	Mo\ubY5lfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MX[yN\|kzOjh6Nh?=
L3.6pl	NXfGWJBISXCxcITvd4l{KEG\|c3H5	NYXhPYY4OjVxNUCvNVAxKG6P	NFPYZ\|U1QCCq	NV7xNmRKTE2VTx?=	NFqxWHdqdmS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NV\BRmhNOjN7MkK4PFY>
CFPAC-1	MV;BdI9xfG:\|aYOgRZN{[Xl?	NXy1bHBGOjVxNUCvNVAxKG6P	MYG0PEBp	MX;EUXNQ	M2rlcYlv\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NH\VbGozOzl{Mki4Oi=>
HN22	NH3NVZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXuwMVIxKG6P	NYnQSFA3OjRxNEigbC=>	MkfWSG1UVw>?	M3TKXYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[U0h[W6mIHTvd4UuKGSncHXu[IVvfCCvYX7u[ZI>	M4[2NVI{QDd5MkO1
HSC4	NHrsU2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoftNE0zOCCwTR?=	NHXuSWkzPC92ODDo	NFyzRpNFVVOR	MkTlbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lMUBidmRiZH;z[U0h\GWyZX7k[Y51KG2jbn7ldi=>	NI[yeVMzOzh5N{KzOS=>
HN22	M3LpTmFxd3C2b4Ppd{BCe3OjeR?=	M{\PelAuOjBibl2=	MWG0PEBp	NFz6VFdFVVOR	MV\pcoR2[2W\|IHPlcIwh[XCxcITvd4l{	MnXiNlM5Pzd{M{W=
HSC4	MnnvRZBweHSxc3nzJGF{e2G7	NHPBZoUxNTJyIH7N	MoDpOFghcA>?	NVHUd49KTE2VTx?=	MoXWbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	NUCwc4RwOjN6N{eyN\|U>
HN22	MlHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2i5dVAuOjBibl2=	NFradXI1QCCq	M4PVXWROW09?	MUjpcoR2[2W\|IFexJJBp[XOnIHPlcIwh[3mlbHWgZZJz\XO2wrC=	M2XkPVI{QDd5MkO1
HSC4	M2XvUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWCwMVIxKG6P	MXO0PEBp	NVvvcnRFTE2VTx?=	NGfYe3NqdmS3Y3XzJGcyKHCqYYPlJINmdGxiY4njcIUh[XK{ZYP0xsA>	M4HSZlI{QDd5MkO1
HN22	MnnwSpVv[3Srb36gRZN{[Xl?	MmOzNE0zOCCwTR?=	MUm0PEBp	NF\PPXlFVVOR	MojKd5VxeHKnc4Pld{BUeDFiZYjwdoV{e2mxbtMg	NETiOngzOzh5N{KzOS=>
HSC4	M1ToUmZ2dmO2aX;uJGF{e2G7	NGHSdpYxNTJyIH7N	NHzRTJQ1QCCq	MmTHSG1UVw>?	M1jVd5N2eHC{ZYPz[ZMhW3BzIHX4dJJme3Orb39CpC=>	MVeyN\|g4PzJ\|NR?=
Cal62	NFjTPZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGrhTHpKSzVyPUOzJOKyKDRibl2=	M3i0XlI{QDJ2ME[0
Hth7	NIHLVWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFjEW2VKSzVyPUG1JOKyKDJibl2=	MXWyN\|gzPDB4NB?=
Hth83	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGrMNGxKSzVyPUO0JOKyKDVibl2=	MoC3NlM5OjRyNkS=
C643	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTdzINMxJFExKG6P	M3fsV\|I{QDJ2ME[0
SW1736	NUDtZlBPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIrNOHVKSzVyPUO1JOKyKDhibl2=	NXfXRVlZOjN6MkSwOlQ>
T241	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHjFN5VKSzVyPU[1JOKyKDdibl2=	MX6yN\|gzPDB4NB?=
T351	MnXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkGwTWM2OD13MDFCtUAyOCCwTR?=	MoXsNlM5OjRyNkS=
BHP2-7	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\nV3FKSzVyPUO3JOKyKDZibl2=	NELrTnkzOzh{NEC2OC=>
T238	M2DoOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TrfWlEPTB;MTy1NFAhyrFiMkCwJI5O	NVn6PXBKOjN6MkSwOlQ>
HCT8	M3H4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1v0fVczKGh?	M3jCRmROW09?	MYjJR\|UxRTF{LkpihKnDueLCiUGuPUBvVQ>?	MlrpNlMzQTl\|OEi=
H630	MlnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoixO\|IhcA>?	MoH6SG1UVw>?	NFm4bVhKSzVyPUGyMlTjiIoEsfMAjVMvOSCwTR?=	MVuyN\|I6QTN6OB?=
cH630 5-FU-res	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NH:xN4k4OiCq	NVXYR\|hITE2VTx?=	M{jnZmlEPTB;MUWuOgKBkcLz4pEJNU4zKG6P	MWeyN\|I6QTN6OB?=
HCT116	M4TYb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHvCcmM4OiCq	MYnEUXNQ	M4DwW2lEPTB;MUCuO-KBkcLz4pEJNk4zKG6P	M2XkfFI{Ojl7M{i4
HCT116 p53−/−	M3vFSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1\WfVczKGh?	NVH6b5FZTE2VTx?=	Mn7VTWM2OD16LkdihKnDueLCiUGuO{BvVQ>?	Mo[3NlMzQTl\|OEi=
dHCT116 p21−/−	NWTUNHp5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{fVeVczKGh?	M3i3PWROW09?	NG\EXnJKSzVyPUWuPgKBkcLz4pEJNU4{KG6P	M3vJb\|I{Ojl7M{i4
HT29	NF\qZYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1TiZ\|czKGh?	MlHSSG1UVw>?	NVSyNZBnUUN3ME2xOk4{6oDLwsJihKkzNjNibl2=	MWmyN\|I6QTN6OB?=
LoVo	NXj1V2h[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWLiZoo{PzJiaB?=	M1XHVmROW09?	NFHBcJFKSzVyPUWuNgKBkcLz4pEJNE43KG6P	MVmyN\|I6QTN6OB?=
RKO	NWLQOohnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUW3NkBp	NFSzO2pFVVOR	Mn6xTWM2OD15LkpihKnDueLCiUKuNkBvVQ>?	MWWyN\|I6QTN6OB?=
SW480	NF73NHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3LEflczKGh?	M{\mXGROW09?	M{LMb2lEPTB;MUeuOgKBkcLz4pEJNE45KG6P	NHjqVIczOzJ7OUO4PC=>
eSW620	NULLZ\|dHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1;vVVczKGh?	NGHQdppFVVOR	M3nhTGlEPTB;OT6x5qCKyrIkgJmyMlEhdk1?	NET1foYzOzJ7OUO4PC=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	DNMT1 / EZH2; PubMed: 19279403 Cancer Biol Ther Western blot of DNMT1 and EZH2 in K562 and LAMA84 following 24 hours treatment with the indicated doses of panobinostat (PS). The levels of β-actin served as the loading control. caspase-8 / cleaved caspase-8 / Sp1; PubMed: 27738323 Oncotarget The indicated MM cell lines were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of caspase-8, cleaved caspase 8 and Sp1 were analyzed by Western blotting. c-Myc / IRF4; PubMed: 27738323 Oncotarget RPMI8226 cells were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of cMyc and IRF4 were analyzed by Western blotting. Ac-H3 / cleaved caspase-3 / CCND1 / ID1 / ID2 / ID3 / ID4 / Synaptophysin / NeuroD1; PubMed: 28915627 Oncotarget Immunoblotting of whole cell lysates prepared from MB cells treated with panobinostat. The representative western blot result shows panobinostat clearly regulated acetyl-Histone H3 (Ac-H3), cleaved caspase-3, CCND1, IDs, synaptophysin and NeuroD1. RAD51 / BRCA1 / CHK1 / RPL13a; PubMed: 24244429 PLoS One CTS, OCI-AML3 or U937 AML cells were treated with variable concentrations of panobinostat for 48 h. Whole cell lysates were subjected to Western blotting to measure protein levels for BRCA1, CHK1, and RAD51 in the cells. H3K9AC / H3K18AC / H3K56AC / H3 / H4K8AC / H4K16AC / H4 / p21 / p27 / cleaved PARP; PubMed: 31071955 Int J Mol Sci Immunoblot analyses of histone acetylation (H3K9AC, H3K18AC, H3K56AC, H4K8AC and H4K16AC), cell cycle arrest (p27 and p27) and apoptotic-related protein (C-Caspase 3 and C-PARP) expression following various panobinostat treatments for 6 h and 24 h on K562 cells. H3, H4 and GAPDH immunoblots served as internal controls.	19279403 27738323 28915627 24244429 31071955
Immunofluorescence	Synaptophysin / NACM; PubMed: 28915627 Oncotarget Panobinostat treated cells are positive for (B) synaptophysin (red) and (C) NCAM (red). Scale bars, 50 μm. α-tubulin / Acetyl-α-tubulin; PubMed: 29983882 Oncotarget CLBL-1 cells were treated with 10 nM of panobinostat for 24 h and then microtubules were visualized by immunofluorescence labeling using antibodies against tubulin and acetylated tubulin (ac-tubulin) using the appropriate excitation and emission filters as described in the material and methods section. Representative microphotographs with tubulin and ac-tubulin labeling (green) and DAPI stained-nuclei (blue) at 100× magnification are shown. Scale bar, 5 μm. BiP; PubMed: 23544167 Transl Oncol Immunofluorescence analysis of BiP after 24 and 48 hours of treatment in HepG2 (upper panel) and Hep3B (lower panel) cells with 0.1 µM panobinostat and 10 nM thapsigargin, showing an increase and a different protein distribution in panobinostat-treated cells, comparable to 10 nM thapsigargin effect, used as a positive control. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm. ATF4; PubMed: 23544167 Transl Oncol HepG2 (left panel) and Hep3B (right panel) cells were treated for 24 and 48 hours with 0.1 µM panobinostat and the immunofluorescence results show an increase of ATF4 and its nuclear localization in both cell lines. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm. IRE1α / S724-IRE1α; PubMed: 23544167 Transl Oncol Analysis of IRE1α/XBP1 involvement. Immunofluorescence results of IRE1α and its phosphorylated form in HepG2 (A) and Hep3B (B) cell lines after 24 and 48 hours of treatment with 0.1 µM panobinostat. The results indicate that panobinostat induces an increase of both the total and the phosphorylated form of IRE1α and a spotted distribution of this protein (enlargement showed for phospho-IRE1α, B). Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.	28915627 29983882 23544167
Growth inhibition assay	Cell viability; PubMed: 27738323 Oncotarget The indicated MM cell lines were cultured in triplicate in the absence or presence of panobinostat at the indicated concentrations. After culturing for 48 hours, cell viability was measured by a WST-8 cell proliferation assay. Results were expressed as the mean +/− SD.	27738323

体内研究

LBH589作用于患肺癌和间皮瘤动物模型,明显降低肿瘤生长，与对照组相比平均降低62%。LBH589作用于免疫活性鼠和严重联合免疫缺陷鼠效果差不多，说明LBH589抑制肿瘤生长与免疫学无关。LBH589按20 mg/kg剂量腹腔注射，每周持续5天，导致在实验最后肿瘤生长平均下降70%。与相应的对照组肿瘤相比，LBH589作用于H526衍生的肿瘤下降53%，作用于BK-T衍生的肿瘤下降81%, 作用于RG-1衍生的肿瘤下降76%，作用于H69衍生的肿瘤下降 70%。在相同条件和剂量的情况下，LBH589 作用于NSCLC和Meso衍生的移植瘤，导致SCLC衍生的肿瘤中有两种衰退，伴随着BK-T衍生的平均肿瘤尺寸从实验开始时的296 mm³降低到实验结束时的116 mm³，RG-1衍生的平均肿瘤尺寸从实验开始时的185mm³降低到实验结束时的86 mm³。^[2]

细胞实验：^[1]	+ 展开 Cell lines: MOLT-4细胞和Reh(前体B细胞) Concentrations: 50 nM Incubation Time: 48小时 Method: 没有处理的细胞和LBH589处理的细胞[人类急性成淋巴细胞性白血病MOLT-4(T 细胞)和Reh(前体-B细胞)]用膜联蛋白V和碘化丙啶染色，然后加入膜联蛋白V-FITC细胞凋亡检测试剂盒I。通过流式细胞仪测定细胞凋亡和不能存活细胞的百分比。用CyAn ADP Violet细胞计数器收集至少5×10⁴个细胞。根据所有的膜联蛋白V-阳性和膜联蛋白V/PI-阳性细胞细胞计算凋亡百分比，根据所有的膜联蛋白V-阳性和PI-阳性及膜联蛋白V/PI-阳性细胞计算细胞活力丢失百分比。 (Only for Reference)
动物实验：^[2]	+ 展开 Animal Models: 携带10×10⁶个M30细胞或5×10⁶个A549细胞的SCID鼠 Formulation: 溶于水的5%葡萄糖 Dosages: 10 mg/kg, 20 mg/kg Administration: 腹腔注射 (Only for Reference)

参考文献

+ 展开

溶解度 (25°C)

体外	DMSO	69 mg/mL (197.46 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 2% DMSO+48% PEG 300+2% Tween 80+ddH2O	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Panobinostat (LBH589) SDF

分子量	349.43
化学式	C₂₁H₂₃N₃O₂
CAS号	404950-80-7
稳定性	3 years -20°C powder
稳定性	2 years -80°C in solvent
别名	NVP-LBH589

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03878524	Not yet recruiting	Breast Cancer\|Prostate Cancer\|Pancreatic Cancer\|Acute Myelogenous Leukemia	OHSU Knight Cancer Institute\|Oregon Health and Science University\|Prospect Creek Foundation	March 14 2019	Phase 1
NCT03632317	Recruiting	Glioma\|Diffuse Intrinsic Pontine Glioma	University of Michigan Rogel Cancer Center	March 2019	Phase 2
NCT03878524	Not yet recruiting	Breast Cancer\|Prostate Cancer\|Pancreatic Cancer\|Acute Myelogenous Leukemia	OHSU Knight Cancer Institute\|Oregon Health and Science University\|Prospect Creek Foundation	March 14 2019	Phase 1
NCT03632317	Recruiting	Glioma\|Diffuse Intrinsic Pontine Glioma	University of Michigan Rogel Cancer Center	March 2019	Phase 2
NCT03566199	Recruiting	Diffuse Intrinsic Pontine Glioma	Sabine Mueller MD PhD\|Midatech Pharma US Inc.\|Pacific Pediatric Neuro-Oncology Consortium\|University of California San Francisco	May 22 2018	Phase 1\|Phase 2
NCT03566199	Recruiting	Diffuse Intrinsic Pontine Glioma	Sabine Mueller MD PhD\|Midatech Pharma US Inc.\|Pacific Pediatric Neuro-Oncology Consortium\|University of California San Francisco	May 22 2018	Phase 1\|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
How to reconstitute the compound for in vivo mice study?
回答：
We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

选择性强的HDAC抑制剂

RGFP966 : HDAC3-selective, IC50=80 nM.
选择性强的HDAC抑制剂

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
活性最高的HDAC抑制剂

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA批准的HDAC抑制剂

Vorinostat (SAHA, MK0683) : Approved by FDA for cutaneous T cell lymphoma.
最新的HDAC抑制剂

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

研究领域

产品类型

Panobinostat (LBH589)

客户使用Selleck该产品发表文献52篇：

产品安全说明书

HDAC抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Panobinostat (LBH589) SDF

计算器

摩尔浓度计算器

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-03-27)

技术支持

常见问题及建议解决方法

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品